Therapeutic Potential of Human Amylin Analogues in Diabetes Mellitus

ISSN： 1173-8804

Source： BioDrugs, Vol.10, Iss.1, 1998-07, pp. : 1-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gastric Inhibitory Polypeptide Analogues: Do They Have a Therapeutic Role in Diabetes Mellitus Similar to That of Glucagon-Like Peptide-1?

By Holst J.J.

BioDrugs, Vol. 16, Iss. 3, 2002-01 ,pp. : 175-181

Adis International

Access to resources Recommend Favorite

Gene and Cell Therapies for Diabetes Mellitus: Strategies and Clinical Potential

By Giannoukakis N.

BioDrugs, Vol. 16, Iss. 3, 2002-01 ,pp. : 149-173

Adis International

Access to resources Recommend Favorite

Pathophysiology of Immune-Mediated (Type 1) Diabetes Mellitus: Potential for Immunotherapy

By Abel M. Krokowski M.

BioDrugs, Vol. 15, Iss. 5, 2001-05 ,pp. : 291-301

Adis International

Access to resources Recommend Favorite

Pramlintide in the Treatment of Diabetes Mellitus

By Edelman Steve

BioDrugs, Vol. 22, Iss. 6, 2008-01 ,pp. : 375-386

Adis International

Access to resources Recommend Favorite

Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide: Potential Applications in Type 2 Diabetes Mellitus

By Meier J.J.

BioDrugs, Vol. 17, Iss. 2, 2003-01 ,pp. : 93-102

Adis International

Access to resources Recommend Favorite